Critical Reviews in Oncology / Hematology
Volume 76, Issue 1 , Pages 1-12 , October 2010

Ovarian function, reproduction and strategies for fertility preservation after breast cancer

  • Federica Tomao

      Affiliations

    • Department of Obstetrics and Gynecology, University of Rome “Sapienza”, Italy
    • Department of Experimental Medicine, University of Rome “Sapienza”, viale R. Elena 324, Italy
    • ,
  • Gian Paolo Spinelli

      Affiliations

    • Department of Experimental Medicine, University of Rome “Sapienza”, viale R. Elena 324, Italy
    • ,
  • Pierluigi Benedetti Panici

      Affiliations

    • Department of Obstetrics and Gynecology, University of Rome “Sapienza”, Italy
    • ,
  • Luigi Frati

      Affiliations

    • Department of Experimental Medicine, University of Rome “Sapienza”, viale R. Elena 324, Italy
    • ,
  • Silverio Tomao

      Affiliations

    • Department of Experimental Medicine, University of Rome “Sapienza”, viale R. Elena 324, Italy
    • Corresponding Author InformationCorresponding author. Department of Experimental Medicine, University of Rome “Sapienza”, Rome, Italy. Fax: +39 06 4997 3028.

,Accepted 16 December 2009.

References 

  1. Spitz S. The histological effects of nitrogen mustard on human tumours and tissues. Cancer. 1948;1:383–398
  2. Meistrich ML, Finch M, da Cunha MF, Hacker U, Au WW. Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res. 1982;42:122–131
  3. Clark ST, Radford JA, Crowther D, Swindell R, Shalet SM. Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol. 1995;13:134–139
  4. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985;21:601–605
  5. Kreuser ED, Xiros N, Hetzel WD, Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. J Cancer Res Clin Oncol. 1987;113:260–266
  6. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med Pediatr Oncol. 1996;27:74–78
  7. Wallace WH, Shalet SM, Lendon M, Morris-Jones PH. Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia. Int J Androl. 1991;14:312–319
  8. Jerzy E, Tyczynski FB, Maxwell Parkin D, ENCR Cancer facts sheets In: Breast cancer in Europe, vol. 2; December 2002.
  9. Hankey BF, Miller B, Curtis R, et al. Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr. 1994;16:7–14
  10. Ghafoor A, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity. CA Cancer J Clin. 2003;53:342–355
  11. Higgins S, Haffty BG. Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer. 1994;73:2175–2180
  12. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–1729
  13. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352:930–942.
  14. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344:1997–2008
  15. Thewes B, Meiser B, Taylor A, et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol. 2005;23:5155–5165
  16. Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23:4347–4353
  17. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22:4174–4183
  18. Degner LF, Kristjanson LJ, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA. 1997;277:1485–1492
  19. Chapman RM. Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol. 1982;9:84–94
  20. Vujovic S. Aetiology of premature ovarian failure. Menopause Int. 2009;15(June (2)):72–75Review
  21. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–2370
  22. Vegetti W, Marozzi A, Manfredini E, et al. Premature ovarian failure. Mol Cell Endocrinol. 2000;161:53–57
  23. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990;1:183–188
  24. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with nodepositive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16:2651–2658
  25. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000;169:123–131
  26. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radiochemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma. 1999;33:65–76
  27. Warne GL, Feirley KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. New Engl J Med. 1973;289:1159–1162
  28. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy patients: results from a randomized trial. J Natl Cancer Inst. 2005;97:1724–1733
  29. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at MD Anderson Hospital and Tumor Institute. J Natl Cancer Inst Monogr. 1986;1:105–109
  30. Davis L, Klitus M, Mintzer D. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin Breast Cancer. 2005;6(5):421–424
  31. Tham YL, Sixton K, Weiss H, Elledge R, Friedman L, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treatd with adjuvant doxorubicin and cyclophosphamide followed by taxane. Am J Clin Oncol. 2007;30:126–132
  32. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapyinduced, long-term amenorrhea in patients with breast carcinoma aged 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104(8):1575–1579
  33. Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer patients: interim analysis of the BCIRG 001 study. Proc Ann Meet Am Soc Clin Oncol. 2002;141:(abstract)
  34. Ferretti G, Carlini P, Bria E, et al. Chemotherapy-induced amenorrhea in early breast cancer. Ann Oncol. 2006;17(2):352
  35. Abusief ME, Missmer SA, Ginsburg Weeks JC, Wiener EP, Partridge AH, The effect of paclitaxel, dose density and trastuzumab in chemotherapy-related amenorrhea (CRA) in premenopausal women with breast cancer, San Antonio; 2006, Abstract 2079
  36. Martin M, Pienkowski T, Mackey J, et al. Breast Cancer International Research Group 001 Investigators: adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313
  37. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24:1045–1051
  38. Berliere M, Dalenc F, Malingret N, et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer. 2008;February (8):56
  39. Danforth DN. How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology (Williston). 1991;5:23–30discussion 30–21
  40. Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT. Should women be advised against pregnancy after breast-cancer treatment?. Lancet. 1997;350:319–322
  41. Hortobagyi GN. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004;100:465–469
  42. Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. BMJ. 2007;334:194
  43. Barthelmes L, Davidson LA, Gaffney C, Gateley CA. Pregnancy and breast cancer. BMJ. 2005;330:1375–1378
  44. Mintzer D, Glassburn J, Mason BA, Sataloff D. Breast cancer in the very young patient: a multidisciplinary case presentation. Oncologist. 2002;7:547–554
  45. Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004;100:465–469
  46. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: “healthy mother effect. Am J Obstet Gynecol. 1994;170:818–823
  47. Von Schoultz E, Johansson H, Wilking N, Rutqvist LE. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol. 1995;13:430–434
  48. Partridge AH, Ruddy KJ. Fertility and adjuvant treatment in young women with breast cancer. Breast. 2007;16(December (Suppl. 2)):S175–S181
  49. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. The Oncologist. 2006;11:422–434
  50. Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med. 1981;304:1377–1382
  51. Meistrich ML, Vassilopoulou-Sellin R, Lipshultz LI. Gonadal dysfunction. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles and practice of oncology, vol. 7. Philadelphia: Lippincott Williams and Wilkins; 2005;p. 25602574
  52. Ataya K, Rao LV, Lawrence E, et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod. 1995;52:365–372
  53. Ataya K, Pydyn E, Ramahi-Ataya A, et al. Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonists?: preliminary observations. J Clin Endocrinol Metab. 1995;8:790–795
  54. Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 1996;11:1620–162620
  55. Blumenfeld Z, Avivi I, Ritter M, et al. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig. 1999;6:229–239
  56. Franke HR, Smit WM, Vermes I. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy. Gynecol Endocrinol. 2005;20:274–278
  57. Recchia F, Sica G, De Filippis S, et al. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs. 2002;13:417–424
  58. Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Ovarian protection with goserelin during adjuvant chemotherapy for premenopausal women with early breast cancer (EBC). Breast Cancer Res Treat Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Breast Cancer Res Treat. 2008;110(August (3)):411–416
  59. Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist. 2007;12:1055–1066
  60. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–2931
  61. Seli E, Tangir J. Fertility preservation options for female patients with malignancies. Curr Opin Obstet Gynecol. 2005;17:299–308
  62. Maltaris T, Seufert R, Fischl F, et al. The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol. 2007;130:148–155
  63. Oktay K, Buyuk E, Davis O, et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18:90–95
  64. Omland AK, Fedorcsak P, Storeng R, et al. Natural cycle IVF in unexplained, endometriosisassociated and tubal factor infertility. Hum Reprod. 2001;16:2587–2592
  65. Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91:3885–3890
  66. Gosden RG. Prospects for oocyte banking and in vitro maturation. J Natl Cancer Inst Monogr. 2005;34:60–63
  67. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006;86:70–80
  68. Chian RC, Buckett WM, Tulandi T, Tan SL. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Hum Reprod. 2000;15:165–170
  69. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007;43:1646–1653
  70. Baka SG, Toth TL, Veeck LL, Jones HW, Muasher SJ, Lazendorf SE. Evaluation of the spindle apparatus of in-vitro matured human oocytes following cryopreservation. Hum Reprod. 1995;10:1816–1820
  71. Oktay K, Tilly J. Livebirth after cryopreserved ovarian tissue autotransplantation. Lancet. 2004;364:2091–2092
  72. Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med. 2000;342:1919
  73. Oktay K, Economos K, Kan M, et al. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA. 2001;286:1490–1493
  74. Callejo J, Salvador C, Miralles A, et al. Long-term ovarian function evaluation after autografting by implantation with fresh and frozen-thawed human ovarian tissue. J Clin Endocrinol Metab. 2001;86:4489–4494
  75. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364:1405–1410
  76. Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005;353:318–321
  77. Liede A, Narod SA. Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat. 2002;20:413–424
  78. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609–161522
  79. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995;80:2918–2925
  80. Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94:606–616.
  81. Park M, Davidson R, Fox K. Preservation of fertility and the impact of subsequent pregnancy in patient with premenopausal breast cancer. Semin Oncol. 2006;33:664–671
  82. Steiner AZ, Terplan M, Paulson R. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod. 2005;20:1511–1515
  83. Klijn JG, Beex LV, Mauriac L. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92:903–911
  84. Casper RF. Aromatase inhibitors in ovarian stimulation. J Steroid Biochem Mol Biol. 2007;106:71–75
  85. Klopper A, Hall M. New synthetic agent for the induction of ovulation: preliminary trials in women. Br Med J. 1971;1:152–154
  86. Boostanfar R, Jain JK, Mishell DR, et al. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil Steril. 2001;75:1024–1026
  87. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002;359:2131–2139
  88. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  89. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305–309
  90. Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91:3885–3890

PII: S1040-8428(09)00262-5

doi: 10.1016/j.critrevonc.2009.12.005

Critical Reviews in Oncology / Hematology
Volume 76, Issue 1 , Pages 1-12 , October 2010

Article Tools